Loading...
Loading...
GLSI| Name | Value |
|---|---|
| Revenues | 3.6K |
| Cost of Revenue | 1.8K |
| Gross Profit | 1.8K |
| Operating Expense | 8,085.1K |
| Operating I/L | -8,084.2K |
| Other Income/Expense | 43.9K |
| Interest Income | 43.9K |
| Pretax | -8,040.2K |
| Income Tax Expense | 0.0K |
| Net Income/Loss | -8,040.2K |
Greenwich LifeSciences, Inc. is a clinical stage biopharmaceutical company specializing in the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate, GP2, is an immunotherapy designed to prevent breast cancer recurrences in patients who have undergone surgery. The company completed a Phase IIb clinical trial for GP2. Greenwich LifeSciences, Inc. generates revenue through the development and potential commercialization of its immunotherapies for cancer treatment.
